EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Early clinical experience with vericiguat after acute decompensated heart failure in elderly patients with HFrEF: a prospective observational study

Domenico Acanfora, Giuseppe Rengo, Chiara Acanfora, Paolo Calabrò, Gennaro Galasso, Raffaele Antonelli Incalzi, Klara Komici, Vincenzo Provitera, Giuseppe Caporaso, Gerardo Casucci

Internal and Emergency Medicine · 13.11.2026

DOI: 10.1007/s11739-026-04588-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal and Emergency Medicine, online erschienen am 13.11.2026. Verfasst von Domenico Acanfora und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, San Francesco Hospital, Viale Europa 21, 82037, Telese Terme, BN, Italy. domenico.acanfora29@gmail.com. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vericiguat has demonstrated clinical benefit in patients with heart failure with reduced ejection fraction (HFrEF), particularly in those at high risk of recurrent heart failure events. However, evidence regarding its early use in elderly patients following hospitalization for acute decompensated HF (ADHF) remains limited. In this prospective single-center case series, 143 consecutive patients aged > 70 years hospitalized for ADHF with HFrEF were enrolled and vericiguat was administrated. Clinical evaluations, left ventricular ejection fraction (LVEF), six-minute walk test (6MWT), Minnesota Living with Heart Failure Questionnaire (MLHFQ), and laboratory parameters were assessed at baseline and after 4 weeks. After 4 weeks of treatment with vericiguat, 44.8% of patients were in NYHA class II and 55.2% in NYHA class III, no patients were in NYHA class IV (p < 0.001); LVEF improved from 34 ± 4.7% to 46.8 ± 7.5% (p < 0.0001); exercise capacity increased significantly (p < 0.001), while a significant decrease in MLHF-Q, NT-proBNP levels and hsCRP was observed (p < 0.001). No symptomatic hypotension, syncope or relevant deterioration in renal function or electrolytes occurred during the observation period. In this single-arm cohort of older patients with HFrEF recently stabilized after ADHF, initiation of vericiguat was feasible and coincided with substantial short-term changes in functional status, LVEF, and circulating biomarkers, without major safety signals during 4 weeks of observation. Given the absence of a control group, these changes cannot be attributed to vericiguat and may reflect, at least in part, recovery from the acute event, decongestion, optimization of background therapy, learning effects, and regression to the mean. These findings should therefore be considered descriptive and hypothesis-generating and require confirmation in controlled studies.

Schlagwörter

Stichwörter der Autor:innen

Acute decompensationBiomarkersExercise capacityHeart failureVericiguat

Autor:innen und Institutionen

  • Department of Internal Medicine, San Francesco Hospital, Viale Europa 21, 82037, Telese Terme, BN, Italy. domenico.acanfora29@gmail.com.
  • Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
  • Istituti Clinici Scientifici ICS Maugeri, S.P.A, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Scientifico di Telese Terme, Telese, Italy.
  • Vascular and Interventional Radiology Unit, Azienda Ospedaliera Universitaria San Giovanni Di Dio e Ruggi d'Aragona, University of Salerno, Salerno, Italy.
  • Division of Clinical Cardiology, Department of Translational Medical Sciences, AORN Sant'Anna e San, University of Campania "Luigi Vanvitelli", Caserta, Italy.
  • Department of Medicine, Surgery, and Dentistry, Azienda Ospedaliera Universitaria San Giovanni Di Dio e Ruggi d'Aragona, University of Salerno, Salerno, Italy.

Zitieren

APA

Acanfora, D., Rengo, G., Acanfora, C., Calabrò, P., Galasso, G., Incalzi, R. A., Komici, K., Provitera, V., Caporaso, G., & Casucci, G. (2026). Early clinical experience with vericiguat after acute decompensated heart failure in elderly patients with HFrEF: a prospective observational study. Internal and Emergency Medicine. https://doi.org/10.1007/s11739-026-04588-4

Vancouver

Acanfora D, Rengo G, Acanfora C, Calabrò P, Galasso G, Incalzi RA, et al. Early clinical experience with vericiguat after acute decompensated heart failure in elderly patients with HFrEF: a prospective observational study. Internal and Emergency Medicine. 2026. doi:10.1007/s11739-026-04588-4

BibTeX
@article{Acanfora2026,
  author = {Acanfora, Domenico and Rengo, Giuseppe and Acanfora, Chiara and Calabrò, Paolo and Galasso, Gennaro and Incalzi, Raffaele Antonelli and Komici, Klara and Provitera, Vincenzo and Caporaso, Giuseppe and Casucci, Gerardo},
  title = {Early clinical experience with vericiguat after acute decompensated heart failure in elderly patients with HFrEF: a prospective observational study},
  journal = {Internal and Emergency Medicine},
  year = {2026},
  doi = {10.1007/s11739-026-04588-4}
}
Kostenlos starten →